false
0001697532
0001697532
2023-11-09
2023-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 9, 2023
APPLIED THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-38898 |
|
81-3405262 |
(State or Other Jurisdiction of
Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
545 Fifth Avenue, Suite 1400 New York, NY 10017 |
|
10017 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number,
including area code: (212) 220-9226
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock |
|
APLT |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On November 9, 2023, Applied Therapeutics, Inc. (the “Company”)
issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided in this Form 8-K, including Exhibit 99.1
hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibit is attached with this current report on Form 8-K:
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
APPLIED THERAPEUTICS, INC. |
|
|
|
Dated: November 9, 2023 |
By: |
/s/ Shoshana Shendelman |
|
Name: |
Shoshana Shendelman |
|
Title: |
President and Chief Executive Officer |
Exhibit 99.1
Applied Therapeutics Reports Third Quarter 2023
Financial Results
Regulatory submissions on track for govorestat
(AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023
Two Upcoming Phase 3 Trial Readouts, with ARISE-HF
Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol
Dehydrogenase (SORD) Deficiency in 1Q 2024
NEW YORK, November 9, 2023 - Applied
Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against
validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30,
2023.
“We have continued to make progress across our late-stage pipeline
and have several key regulatory and clinical inflection points expected later this quarter and in early 2024,” said Shoshana Shendelman,
PhD, Founder, Chief Executive Officer, and Chair of the Board. “We are working expeditiously to submit our regulatory filings for
govorestat (AT-007) for the treatment of Classic Galactosemia in both the U.S. and in Europe and look forward to providing updates as
those submissions occur. In tandem, we are soon approaching Phase 3 readouts for our ARISE-HF Trial of AT-001 (caficrestat) in Diabetic
Cardiomyopathy (DbCM) and our INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase (SORD) Deficiency, which are expected in 4Q23 and
in 1Q24, respectively.”
Recent Highlights
| · | On Track to Submit NDA to the U.S. FDA and MAA to the EMA for Govorestat (AT-007) for the Treatment of Classic Galactosemia in
the Fourth Quarter of 2023. The Company is working to submit a New Drug Application (NDA) to the United States Food and Drug Administration
(U.S. FDA) for govorestat for the treatment of Galactosemia. As previously announced, the Company held a successful pre-NDA meeting with
the FDA regarding the govorestat Galactosemia program. Based on discussions with the FDA, the Company believes they are aligned with the
FDA and plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in the fourth quarter of this year. Regarding
regulatory submission plans in Europe, the Company and its European commercial partner, Advanz Pharma, expect to submit a Marketing Authorization
Application (MAA) to the European Medicines Agency (EMA) this quarter. |
| · | Hosted an Expert Forum
on Diabetic Cardiomyopathy with Leading Cardiologists. In November 2023, the Company
hosted a KOL discussion on Diabetic Cardiomyopathy (DbCM) led by James Januzzi, MD, Hutter
Family Professor of Medicine, Harvard Medical School, Director, Dennis and Marilyn Barry
Fellowship in Cardiology Research, Massachusetts General Hospital Gregory Lewis, MD, Director,
Cardiopulmonary Exercise Testing Laboratory and Section Head, Heart Failure, Massachusetts
General Hospital. The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety
and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional
capacity in Diabetic Cardiomyopathy (DbCM). The Company expects topline data from the study
in the fourth quarter of 2023. A replay of the webcast event can be accessed here. |
| · | Presented Baseline Data from Ongoing Phase 3 ARISE-HF Study of AT-001 (caficrestat) in Diabetic Cardiomyopathy at the 2023 European
Association for the Study of Diabetes Annual Meeting. In September 2023, the Company presented baseline data at the 2023 European
Association for the Study of Diabetes (EASD) Annual Meeting from the ongoing Phase 3 ARISE-HF study of AT-001 (caficrestat) in DbCM. Riccardo
Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics, presented the data in an oral Symposium entitled Diabetic Cardiomyopathy
(DbCM): a severe complication of diabetes. The baseline data presented at EASD showed that patients with DbCM exhibit reduced cardiac
functional capacity, resulting in decreased physical capacity, underscoring the negative impact of DbCM on physical function and quality
of life in patients. The data supports the development of AT-001 for the treatment of DbCM and the ongoing ARISE-HF Phase 3 global clinical
trial. |
Financial Results
| · | Cash and cash equivalents and short-term investments totaled $37.5 million as of September 30,
2023, compared with $30.6 million at December 31, 2022. |
| · | Research and development expenses for the three months ended September 30, 2023 were $10.8
million, compared to $13.1 million for the three months ended September 30, 2022. The decrease of approximately $2.3 million
was primarily related to a decrease in clinical and pre-clinical expense of $1.8 million, primarily due to the decrease in expense related
to CROs, a decrease in drug manufacturing and formulation costs of $0.5 million primarily due to the release of legacy accrual in the
three months ended September 30, 2023; an increase in personnel expenses of $10,000; a decrease in stock-based compensation of $0.4
million due to decrease in headcount which resulted in options and restricted stock units being forfeited; and an increase in regulatory
and other expenses of $0.4 million. |
| · | General and administrative expenses were $4.7 million for the three months ended
September 30, 2023, compared to $6.2 million for the three months ended September 30, 2022. The decrease of approximately
$1.5 million was primarily related to an increase in legal and professional fees of $0.7 million due to higher external legal
fees; a decrease in commercial expenses of $0.8 million related to a decrease in spend for commercial operations and release of
legacy accruals for the three months ended September 30, 2023; a decrease in personnel expenses of $0.4 million related to a
decrease in headcount; a decrease in stock-based compensation of $0.6 million relating to options and restricted stock units being
forfeited during the current period as well as decrease in headcount; a decrease in insurance expenses of $0.4 million related to
decreased insurance costs; and a decrease in other expenses of $0.1 million. |
| · | Net loss for the third quarter of 2023 was $42.4 million, or $0.47 per basic and diluted common
share, compared to a net loss of $19.1 million, or $0.40 per basic and diluted common share, for the third quarter 2022. |
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s
lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS
rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent
ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003,
an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
To learn more, please visit www.appliedtherapeutics.com
and follow the company on Twitter @Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking statements”
that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform
Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations,
prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,”
“plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions
or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the timing of data
readouts for our ARISE-HF and INSPIRE trials, (ii) the timing of our plans to submit an NDA and MAA for approval. Forward-looking
statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those
expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or
strategies will be attained or achieved.
Such risks and uncertainties include, without limitation, (i) our
plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current
and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage
of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital
requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates
on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain
and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current
and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations
regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund
our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of
our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the
duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights,
(xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in
the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating
to our competitors and our industry, (xvii) our ability to achieve the anticipated benefits from the agreements entered into in connection
with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant
uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee
that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will
be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements
in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the “Risk Factors”
contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
otherwise.
Contacts
Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com
Media:
media@apliedtherapeutics.com
Applied Therapeutics, Inc.
Condensed Balance Sheets
(in thousands, except share and per share data)
| |
As of | | |
As of | |
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
CURRENT ASSETS: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 37,457 | | |
$ | 16,657 | |
Investments | |
| — | | |
| 13,923 | |
Prepaid expenses and other current assets | |
| 7,031 | | |
| 6,728 | |
Total current assets | |
| 44,488 | | |
| 37,308 | |
Operating lease right-of-use asset | |
| 510 | | |
| 857 | |
Security deposits and leasehold improvements | |
| 197 | | |
| 198 | |
TOTAL ASSETS | |
$ | 45,195 | | |
$ | 38,363 | |
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)/EQUITY | |
| | | |
| | |
CURRENT LIABILITIES: | |
| | | |
| | |
Current portion of operating lease liabilities | |
$ | 491 | | |
$ | 477 | |
Accounts payable | |
| 6,005 | | |
| 4,534 | |
Accrued expenses and other current liabilities | |
| 12,245 | | |
| 14,756 | |
Warrant liabilities | |
| 36,763 | | |
| 13,657 | |
Total current liabilities | |
| 55,504 | | |
| 33,424 | |
NONCURRENT LIABILITIES: | |
| | | |
| | |
Noncurrent portion of operating lease liabilities | |
| 44 | | |
| 414 | |
Clinical holdback - long-term portion | |
| 691 | | |
| 464 | |
Total noncurrent liabilities | |
| 735 | | |
| 878 | |
Total liabilities | |
| 56,239 | | |
| 34,302 | |
STOCKHOLDERS’ (DEFICIT)/EQUITY: | |
| | | |
| | |
Common stock, $0.0001 par value; 200,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 77,133,516 shares issued and outstanding as of September 30, 2023 and 48,063,358 shares issued and outstanding as of December 31, 2022 | |
| 7 | | |
| 5 | |
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | |
| — | | |
| — | |
Additional paid-in capital | |
| 419,856 | | |
| 352,828 | |
Accumulated other comprehensive gain | |
| — | | |
| 51 | |
Accumulated deficit | |
| (430,907 | ) | |
| (348,823 | ) |
Total stockholders' (deficit)/equity | |
| (11,044 | ) | |
| 4,061 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)/EQUITY | |
$ | 45,195 | | |
$ | 38,363 | |
Applied Therapeutics, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
REVENUE: | |
| | |
| | |
| | |
| |
License Revenue | |
$ | — | | |
$ | — | | |
$ | 10,660 | | |
$ | — | |
Total Revenue | |
| — | | |
| — | | |
| 10,660 | | |
| — | |
OPERATING EXPENSES: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 10,785 | | |
$ | 13,116 | | |
$ | 38,602 | | |
$ | 43,542 | |
General and administrative | |
| 4,710 | | |
| 6,240 | | |
| 15,585 | | |
| 20,436 | |
Total operating expenses | |
| 15,495 | | |
| 19,356 | | |
| 54,187 | | |
| 63,978 | |
LOSS FROM OPERATIONS | |
| (15,495 | ) | |
| (19,356 | ) | |
| (43,527 | ) | |
| (63,978 | ) |
OTHER INCOME (EXPENSE), NET: | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 392 | | |
| 227 | | |
| 1,020 | | |
| 414 | |
Change in fair value of warrant liabilities | |
| (27,277 | ) | |
| 36 | | |
| (39,611 | ) | |
| (4,321 | ) |
Other income (expense): | |
| 10 | | |
| (8 | ) | |
| 34 | | |
| (194 | ) |
Total other income (expense), net | |
| (26,875 | ) | |
| 255 | | |
| (38,557 | ) | |
| (4,101 | ) |
Net loss | |
$ | (42,370 | ) | |
$ | (19,101 | ) | |
$ | (82,084 | ) | |
$ | (68,079 | ) |
Net loss attributable to common stockholders—basic and diluted | |
$ | (42,370 | ) | |
$ | (19,101 | ) | |
$ | (82,084 | ) | |
$ | (68,079 | ) |
Net loss per share attributable to common stockholders—basic and diluted | |
$ | (0.47 | ) | |
$ | (0.40 | ) | |
$ | (1.09 | ) | |
$ | (2.02 | ) |
Weighted-average common stock outstanding—basic and diluted | |
| 90,669,969 | | |
| 48,000,183 | | |
| 75,482,234 | | |
| 33,785,386 | |
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De May 2023 a May 2024